← Eichor
Study identifier: NCT06388161 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Neural Autoantibody Prevalence in New-onset Focal Seizures of Unknown Etiology

Condition: Epilepsy · Encephalitis Autoimmune  ·  Sponsor: Shen Chun-Hong

PhaseN/A
Planned participants300
Who can joinAll sexes, 14 Years to 100 Years
Healthy volunteersNo

About this study

Seizure is one of the most common symptoms in autoimmune encephalitis with neuronal surface-mediated antibodies. Interestingly, some patients may exhibit new-onset seizures as the initial manifestation without fulminant sign of encephalitis, particularly in the early stage. It is essential to recognize these patients early and to perform antibody testing, as studies have reported early immunotherapy can improve their clinical outcomes. At the same time, it is important to limit the number of patients who require testing, for the sake of specificity and cost effectiveness. Thus, this prospective, multicenter study aims to identify neural antibodies in patients with focal seizures of unknown etiology, and to create a score to preselect patients requiring autoantibody testing.

This description comes directly from the study's public registry record.

Talk to the study team

Chun-Hong Shen  ·  +86 0571 87783872  ·  shen_neurology@zju.edu.cn

Always discuss trial participation with your own doctor first.

Locations (1)

2nd Affiliated Hospital, School of Medicine, Zhejiang University, ChinaHangzhou, Zhejiang, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06388161